Overview

NCI Definition [1]:
The hydrochloride salt form of diphenhydramine, an ethanolamine and first-generation histamine antagonist with anti-allergic activity. Diphenhydramine hydrochloride competitively blocks H1receptors, thereby preventing the actions of histamine on bronchial smooth muscle, capillaries, and gastrointestinal (GI) smooth muscle. This prevents histamine-induced bronchoconstriction, vasodilation, increased capillary permeability, and GI smooth muscle spasms.

Diphenhydramine hydrochloride has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating diphenhydramine hydrochloride, 1 is phase 2 (1 open).

CD22 Expression is the most frequent biomarker inclusion criterion for diphenhydramine hydrochloride clinical trials.

B-cell acute lymphoblastic leukemia is the most common disease being investigated in diphenhydramine hydrochloride clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Diphenhydramine Hydrochloride
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating diphenhydramine hydrochloride and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
diphenhydramine.hcl, diphenhydramine hydrochloride [chemical/ingredient], diphenhydramine hydrochloride (substance), diphenhydramine hydrochloride, hydrochloride, diphenhydramine, diphenhydramine hydrochloride, sk-diphenhydramine, diphenhydramine hydrochloride, 147-24-0, diphenhydramine hydrochloride, benadryl, bendylate, eldadryl, 33299
NCIT ID [1]:
C300
SNOMED ID [1]:
C-51451

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.